+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Male Infertility Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Pre Book Price: $ 5216

Original Price: $ 5795

Male infertility refers the male inability to cause pregnancy in a fertile female. It is majorly due to low sperm count, hormonal problem or presence of low number of motile sperms. Hence, fertility in male requires normal functioning of hypothalamus, pituitary gland, and testes. However, 40% -50% cases have no identifiable cause and 30% -40% cases are due to problem in the testes. The various causes of increasing infertility in male includes consumption of alcohol and drugs, rising stress level, obesity, smoking, and environmental toxins. Infertility in male diagnosed with various techniques such as DNA fragmentation techniques, oxidative stress analysis, sperm agglutination, sperm penetration assay, microscopic examination, and computer assisted sperm analysis.SpermCheck fertility is a U.S. FDA approved home screening test to determine low sperm count for men in 2012. According to the American Society for Reproductive medicines, in approximately 40% of infertile couples, male partner is sole cause of infertility and about 85% -90% are treated with conventional treatment such as drugs or surgery. 

 

Global male infertility treatment market segmented into drugs, hormonal therapy, and assisted reproductive technology (ART). Drugs used for male infertility treatment are clomiphene citrate,and tamoxifen.Hormonal therapy market further segmented into human chorionic gonadotropinhormone(hCG), and recombinant follicle stimulating hormone (rFSH).Gonadotropin therapy is given to the patients to increase the testosterone level and sperm count. If these therapies are not worked after 6 to 12 months treatment then option is assisted reproductive technologies. Assisted reproductive technology further is segmented intoin vitro fertilization-embryo transfer (IVF-ET), gamete intrafallopian transfer (GIFT), frozen embryo transfer (FET), and zygote intrafallopian transfer (ZIFT). Geographically, male infertility treatment market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and rest of the World. Assisted reproductive technology segment dominated the global market due to higher success rate as compared to the drugs and hormonal therapy. However, doctors suggest ART treatment after the failure of drugs and hormonal treatment. In assisted reproductive technology segment in-vitro fertilization-embryo transfer is the most dominated procedure in 2014. Geographically, the North America is the highest revenue generating market due to more awareness, and reimbursement facility for male infertility treatment. However, Asia Pacific is expected to grow at a highest rate due to rising awareness, and increasing incidence of infertility in men due to changes in the lifestyle.

 

Global male infertility treatment market is anticipated to grow at a faster rate due to the changes in the lifestyle, environmental effect, rising incidence of infertility cases, number of obese people, and increasing consumption of alcohol and drugs. According to the World Health Organization (WHO), globally 1.9 million obese and 600 million people were diagnosed to be overweight. Global organization for stress states that six out of ten people suffer from stress at work place and the highest stress rate was found at China (86%).  However, the major limitation experienced in the male infertility treatment market is due to repeated treatment failures leading to an emotional impact on the patient. The person undergoing immense stress after the diagnosis or repeated failure of the treatment which would further result to intensify the infertility problem andresult in most of the patients to discontinue the treatment. The other limitation is the social taboo, and high cost associated with the treatment. Out of the 40% fertile men, only 15% of the men opt for the treatment for infertility due to the embarrassment, guilt, and other reasons.

 

Some of the major players having presence in the global male infertility treatment market includesParallabs, European Sperm Bank, Origio, Cryolab Ltd., IrvineScientific, Microm UK Limited, and Merck Serono.

 

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of 

  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

 

Reasons for Buying this Report

  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a six-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.


To receive discount, please click on the button below.

Please click on the button below to customize this report.

 
 
Back To Top